Skip to main content
EJNMMI Research
Fig. 6 | EJNMMI Research

Fig. 6

From: Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma

Fig. 6

a Box plots of the SUV values for [18F]FSPG and [18F]FDG at 60 min post-injection (p.i.). The actual SUV values of the individual lesions from the primary tumor are shown as blue dots, and the individual metastatic lesions are shown as red dots. Corresponding [18F]FDG and [18F]FSPG lesion uptake is shown by connecting lines. b Box plots of the tumor-to-muscle (T/M) ratio for [18F]FSPG and [18F]FDG lesion uptake at 60 min p.i.

Back to article page